Table 3.

AT(N) profile by diagnostic group

AT(N) profile	AD	MCI	FTD	LBD and PD	VaD and stroke	Indeterminate	No diagnosis	Total
A-T-(N)-	6	8	8	6	4	21	10	63
A+T-(N)-	11	2	6	1	4	9	2	35
A+T+(N)-	4	1	1	1	0	0	1	8
A+T+(N)+	22	0	2	2	0	4	0	30
A+T-(N)+	5	0	1	0	0	1	0	7
A-T+(N)-	0	0	0	0	0	3	2	5
A-T-(N)+	1	0	0	0	0	1	1	0
A-T+(N)+	5	1	1	0	1	2	0	10
Total	54	12	19	10	9	41	16	161

There was a statistically significant difference between all groups (χ² = 71.22, p = 0.003). AD, Alzheimer’s disease or Alzheimer’s disease atypical variant; MCI, mild cognitive impairment; FTD, frontotemporal dementia; LBD and PD, Lewy’s body dementia and Parkinson’s disease combined; VaD and stroke, vascular dementia and stroke combined; Indeterminate, indeterminate condition; No diagnosis, no neurodegenerative disease; A, biomarker of Aβ plaques (labeled “A”) is low CSF Aβ₄₂; T, biomarker of fibrillary tau (labeled “T”) is elevated CSF phosphorylated tau (P-tau); [N], biomarker of neurodegeneration or neuronal injury [labeled (“N”)] is CSF T-tau.